Preview

Rational Pharmacotherapy in Cardiology

Advanced search

TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON METOPROLOL SUCCINATE

https://doi.org/10.20996/1819-6446-2012-8-6-798-803

Full Text:

Abstract

Advantages of metoprolol succinate in patients with chronic heart failure (CHF) are covered. Results of MERIT-HF study are taken as the main evidences. Patterns of the metoprolol succinate use in the treatment of different categories of patients with CHF (women, the elderly , severe CHF forms, CHF with concomitant hypertension or diabetes) are considered.

About the Authors

O. D. Ostroumova
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation


G. N. Shchukina
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation


V. M. Fomina
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Russian Federation


References

1. National guidelines for diagnosis and treatment of chronic heart failure. Serdechnaya Nedostatochnost' 2010;11(1): 69–160. Russian (Национальные рекомендации по диагностике и лечению хронической сердечной недостаточности. Сердечная недостаточность 2010;11(1): 69–160).

2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001–7.

3. Goldstein S, Fagerberg B, Hjalmarson A et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001;38(4):932–8.

4. National guidelines for diagnosis and treatment of hypertension (4th revision). Sistemye Gipertenzii 2010; (3):5–26. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии (четвертый пересмотр). Системные гипертензии 2010; (3): 5–26).

5. ESC Guidelines for diagnosis and treatment of acute and chronic heart failure. European Heart J 2012; 33: 1787–1847.

6. Deedwania PC, Gottlieb S, Ghali JK et al. Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure. Eur Heart J 2004; 25(15):1300–9.

7. Wikstrand J, Hjalmarson A, Waagstein F, et al.; MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol 2002;40(3):491–8.

8. Ageev F.T., Danielyan M.O., Mareev V. Yu. et al. patients with chronic heart failure outpatients in Russia: peculiarities of this, diagnosis and treatment (The EPOHA-O-HSN study). Serdechnaya Nedostatochnost' 2004;5 (1):4—7. Russian (Агеев Ф.Т., Даниелян М.О., Мареев В. Ю. и др. Больные с хронической сердечной недостаточностью в российской амбулаторной практике: особенности контингента, диагностики и лечения (по материалам исследования ЭПОХА-О-ХСН). Сердечная Недостаточность 2004;5 (1):4—7).

9. Tyurina T.V., Grotova A.V., Krylova L.G., Bukhenskiy I.M.. The efficacy and safety egilok retard in the treatment of hypertension in the elderly. Arterial'naya Gipertenziya 2008;14(1):143–146. Russian (Тюрина Т.В., Гротова А.В., Крылова Л.Г., Бухенский И.М.. Эффективность и безопасность Эгилока Ретард при лечении артериальной гипертензии у пожилых людей. Артериальная Гипертензия 2008;14(1):143–146).

10. Smolenskaya O.G., Zhdanova I.V., Semyatnikova N.M., Silkina N.N. Egilok in the treatment of chronic heart failure in patients with normal and elevated blood pressure. Rossiyskiy Kardiologicheskiy Zhurnal 2002; (4): 48–52. Russian (Смоленская О.Г., Жданова И.В., Семятникова Н.М., Силкина Н.Н. Эгилок в лечении хронической сердечной недостаточности у больных с нормальным и повышенным уровнем АД. Российский кардиологический журнал 2002; (4): 48–52).


For citation:


Ostroumova O.D., Shchukina G.N., Fomina V.M. TREATMENT OF CHRONIC HEART FAILURE: FOCUS ON METOPROLOL SUCCINATE. Rational Pharmacotherapy in Cardiology. 2012;8(6):798-803. (In Russ.) https://doi.org/10.20996/1819-6446-2012-8-6-798-803

Views: 529


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)